Sequential biological immunosuppression. Induction therapy with rabbit antithymocyte globulin

Area of Science:

• Nephrology
• Immunology
• Transplantation Medicine

Background:

• Renal transplantation is a critical treatment for end-stage renal disease.
• Optimizing immunosuppression protocols is essential for improving graft survival and patient outcomes.
• Rabbit anti-human thymocyte IgG (Thymoglobuline) is a potential induction agent in renal transplantation.

Purpose of the Study:

• To evaluate the efficacy and safety of a quadruple sequential immunosuppression protocol using Thymoglobuline in renal allograft recipients.
• To assess the impact of Thymoglobuline on acute rejection rates, graft survival, and patient survival.
• To characterize the side-effect profile of Thymoglobuline in this patient cohort.

Main Methods:

• Retrospective analysis of 108 consecutive renal transplant patients receiving 109 allografts.
• Utilized a quadruple sequential immunosuppression regimen including Thymoglobuline, azathioprine, tapering corticosteroids, and delayed cyclosporine A.
• Monitored serum creatinine, patient survival, allograft survival, and adverse events.

Main Results:

• The quadruple regimen demonstrated favorable 4-year patient survival (96.6%) and allograft survival (83.6%).
• The incidence of acute rejection was 32%, with Thymoglobuline retreatment showing a low rate of recurrent rejection.
• Thymoglobuline was generally well-tolerated, with common side effects including fever, chills, and leucopenia, and a low incidence of other adverse events.

Conclusions:

• Thymoglobuline, as part of a quadruple sequential immunosuppressive regimen, is well-tolerated in renal transplantation.
• This protocol is associated with good short- and long-term outcomes, including favorable graft and patient survival rates.
• Thymoglobuline appears effective in preventing recurrent acute rejection episodes.